CLINICAL TRIALS AND OBSERVATIONS Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort
نویسندگان
چکیده
1Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA; 2New England Research Institutes, Watertown, MA; 3Children’s Memorial Hospital, Chicago, IL; 4University of Texas Southwestern Medical Center at Dallas, Dallas, TX; 5Baylor College of Medicine, Houston, TX; 6University of Toronto, The Hospital for Sick Children, Toronto, ON; 7Weill Cornell Medical College, New York, NY; 8Children’s Hospital & Research Center Oakland, Oakland, CA; 9Children’s Healthcare of Atlanta at Scottish Rite, Atlanta, GA; 10University College London, London, United Kingdom; 11Children’s Hospital of Los Angeles, Los Angeles, CA; 12Toronto General Hospital, Toronto, ON; and 13Children’s Hospital, Boston, MA
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Effect of transfusional iron intake on response to chelation therapy in -thalassemia major
The success of chelation therapy in controlling iron overload in patients with thalassemia major is highly variable and may partly depend on the rate of transfusional iron loading. Using data from the 1-year phase III study of deferasirox, including volumes of transfused red blood cells and changes in liver iron concentration (LIC) in 541 patients, the effect of iron loading on achieving neutra...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia
Patients with thalassemia major require lifelong chelation therapy to prevent ironinduced organ damage. The orally active chelator deferiprone has been proposed as an alternative for patients unable or unwilling to use deferoxamine. One report has concluded that deferiprone may worsen hepatic fibrosis in patients with thalassemia, whereas others have found no detrimental effect. A panel of 3 pa...
متن کاملPlenary Paper CLINICAL TRIALS AND OBSERVATIONS A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA)
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA) Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla M. Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Tomasz Lawniczek, Dany Habr, Marianne Weisskopf, Yiyun Zhang, and Yesim Aydinok, on behalf of the CORDELIA study invest...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up
1Universitá di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 2Centre National de Greffe de Moelle Osseuse, Bab Saadoun, Tunis, Tunisia; 3Istanbul University Medical Faculty, Istanbul, Turkey; 4Suleyman Demirel University Medical Faculty, Isparta, Turkey; 5Ospedale Civico, G Di Cristina e Benfratelli, Palermo, Italy; 6Children’s Hospital ...
متن کاملDeferiprone‐induced agranulocytosis: 20 years of clinical observations
Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC). Here, we analyze all episodes of agranulocytosis (n = 161) and neutropenia (n = 250) during deferiprone use in clinical trials (CT) and postmarketing surveillance programs (PMSP). Rates of agranulocy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2012